Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.52 CAD 2.01% Market Closed
Market Cap: 125.6m CAD

Cardiol Therapeutics Inc
Investor Relations

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

Show more
Loading
CRDL
S&P TSX Composite Index (Canada)
1Y 3Y 5Y 10Y 15Y 20Y

Earnings Calls

No Earnings Calls Available

Management

Mr. David G. Elsley MBA
President, CEO & Director
No Bio Available
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA
CFO, Corporate Secretary & Director
No Bio Available
Mr. Bernard Lim B.Sc.
Chief Operating Officer
No Bio Available
Dr. Andrew Warwick Hamer M.D.
Chief Medical Officer & Head of Research & Development
No Bio Available
Trevor Burns
Investor Relations
No Bio Available
Mr. John A. Geddes BSCPT, MBA
Vice President of Corporate Development
No Bio Available

Contacts

Address
ONTARIO
Oakville
602-2265 Upper Middle Road East
Contacts
+12899100850.0
www.cardiolrx.com
sparklesyt

See Also

Summary
CRDL intrinsic value, competitors valuation, and company profile.
DCF Valuation
CRDL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CRDL stock valuation using valuation multiples.
Wall Street Estimates
CRDL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CRDL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 257,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.